IEX — IDEX Corporation

As of 2026-08-27, market sentiment is bullish: Q2 2026 adjusted EPS of $2.32 beat the ~$2.10-2.11 consensus, revenue of $920.6M beat the ~$902-905M range, and HST organic orders rose 47%, driving total organic orders up 28%. Mizuho upgraded to Outperform with a $280 target, RBC also moved to $280, and the stock has outperformed the S&P 500 over the past year, up roughly 41% versus about 18.7%.

Revenue has been in a clear uptrend: from $788.9M in Q4 2023 to $920.6M in Q2 2026, with YoY growth consistently positive and mostly high-single-digit over the last five quarters: +7.2%, +10.1%, +4.2%, +8.9%, and +6.4%. Operating margin has been stable in the roughly 20-22% range, with Q1 2026 the low point at 19.4% and Q2 2026 recovering to 21.7%. GAAP diluted EPS has drifted higher—$1.93 in Q2 2026 versus $1.26 in Q1 2025—but Q2 2026 includes roughly $0.08 of a non-repeatable tariff refund. This is steady execution and modest acceleration, not a runaway inflection.

At $233.98 as of 2026-08-27, trailing P/E is 33.57, about 7% above the 5-year average of 31.23. Price-to-sales of 4.81 is actually slightly below the 5-year average of 5.13. More importantly, forward P/E is about 26.6x on FY2026 consensus EPS of $8.806, which is within management's $8.70-$8.85 guidance. For a company with 20.8% TTM operating margin, strong free cash flow, and a 1.28% dividend yield, that is reasonable but not cheap. The PEG of 2.66 looks high, but that measure is distorted by low GAAP-based long-term growth assumptions versus the stronger adjusted forward trajectory.

The stock has run hard and now trades roughly in line with forward earnings; trailing GAAP P/E looks elevated because adjusted EPS is meaningfully higher than GAAP EPS. If IEX keeps delivering HST-led organic growth and hits or beats the $8.70-$8.85 range, 26-28x forward EPS supports $240-$260, which is roughly where the Street targets sit. If orders decelerate or margins slip, the multiple could reset toward 24x forward, implying a pullback to the low $210s. The market is paying for continued execution, not for a dramatic growth re-rating.

As of 2026-08-27, RSI was 52.77, squarely neutral—not overbought or oversold. The stock was 0.55% below its 20-day SMA, 2.35% above its 50-day SMA, and 14.61% above its 200-day SMA. That is an intact medium/long-term uptrend with a short-term pause. A pullback toward the 50-day area around $228-230 would offer a better technical entry, while a break back above recent highs near $243-244 would signal renewed upside momentum.

• Data center, semiconductor, and space/defense capex cycles are driving HST order growth, with HST organic orders up 47% in Q2 2026.
• Global industrial production and PMI trends remain mixed, so IDEX's diversified exposure across fluid handling and health/science is important but not immune to industrial softness.
• Interest rates and equity multiple compression risk matter more after a 41% one-year run; the stock is no longer cheap no matter how good the fundamentals are.
• Currency translation remains a recurring headwind/tailwind given IDEX's non-U.S. revenue exposure.
• Tariff and regulatory policy is in flux: a Supreme Court ruling produced a $22.0M cost-of-sales reversal in Q2 2026, but future tariff changes could cut the other way.

• Q3 2026 earnings, expected late October 2026—watch whether HST order momentum holds against tougher comps and whether management raises or simply reaffirms guidance.
• M&A and capacity expansion: management has flagged higher capex and active bolt-on M&A, supported by $621.3M cash and a 3.05 current ratio.
• Continued data center, semiconductor, and space/defense demand could push organic order growth and EPS estimates higher.
• Further analyst price-target upgrades if the stock breaks above its 52-week high near $243.80.

• Valuation risk: 33.6x trailing and ~26.6x forward earnings leaves little room for a growth or margin miss.
• HST/tech-adjacent cyclicality: a slowdown in data center or semiconductor capex would hit IDEX's fastest-growing segment.
• One-off tariff refund inflated Q2 2026 by roughly $0.08 EPS; that benefit does not repeat.
• Currency and soft global industrial demand could pressure revenue growth and margins.
• M&A integration or overpaying for growth businesses is a real risk given management's stated appetite for bolt-on deals.

IDEX is a high-quality, cash-generative industrial franchise with strong HST-driven growth, stable 20%+ operating margins, and a solid balance sheet. But at $233.98 as of 2026-08-27, the stock is fairly valued, with my fair-value estimate around $256. I would not chase it here; a pullback toward the 50-day moving average or a better margin of safety would make the risk/reward more attractive. This is analysis, not personalized financial advice.

Applied a 29x forward P/E to next-FY consensus EPS of $8.806, calibrated between the 5-year average trailing P/E of 31.23 and the current forward multiple of ~26.6x, given IDEX's quality, margins, and HST growth. Cross-checking with a 5.13x average P/S on next-FY revenue yields a similar fair value of roughly $256.50.